Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression.
Brett JO, Dubash TD, Johnson GN, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Lloyd MR, Kambadakone A, Spring LM, Micalizzi DS, Onozato ML, Che D, Nayar U, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Han HS, Iafrate AJ, Ryan LY, Juric D, Moy B, Ellisen LW, Maheswaran S, Wagle N, Haber DA, Bardia A, Wander SA. Brett JO, et al. Among authors: nasrazadani a. JCO Precis Oncol. 2023 May;7:e2200532. doi: 10.1200/PO.22.00532. JCO Precis Oncol. 2023. PMID: 37141550 Free PMC article.
CDK4/6 inhibitors: taking the place of chemotherapy?
Nasrazadani A, Brufsky AM. Nasrazadani A, et al. Lancet Oncol. 2019 Oct;20(10):1329-1330. doi: 10.1016/S1470-2045(19)30507-8. Epub 2019 Sep 4. Lancet Oncol. 2019. PMID: 31494036 No abstract available.
The Evolving Landscape of HER2-Directed Breast Cancer Therapy.
Marti JLG, Hyder T, Nasrazadani A, Brufsky AM. Marti JLG, et al. Among authors: nasrazadani a. Curr Treat Options Oncol. 2020 Aug 7;21(10):82. doi: 10.1007/s11864-020-00780-6. Curr Treat Options Oncol. 2020. PMID: 32767149 Review.
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.
Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, Xi J, Pandey A, Dunne S, Nasrazadani A, Kambadakone A, Stein C, Lloyd MR, Yuen M, Spring LM, Juric D, Kuter I, Sanidas I, Moy B, Mulvey T, Vidula N, Dyson NJ, Ellisen LW, Isakoff S, Wagle N, Brufsky A, Kalinsky K, Ma CX, O'Shaughnessy J, Bardia A. Wander SA, et al. Among authors: nasrazadani a. J Natl Compr Canc Netw. 2021 Mar 24:1-8. doi: 10.6004/jnccn.2020.7662. Online ahead of print. J Natl Compr Canc Netw. 2021. PMID: 33761455
Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer.
Hyder T, Bhattacharya S, Gade K, Nasrazadani A, Brufsky AM. Hyder T, et al. Among authors: nasrazadani a. Breast Cancer (Dove Med Press). 2021 Mar 30;13:199-211. doi: 10.2147/BCTT.S273058. eCollection 2021. Breast Cancer (Dove Med Press). 2021. PMID: 33833568 Free PMC article. Review.
Ovarian function suppression as a potential mechanism of chemotherapy.
Gomez Marti JL, Nasrazadani A, Brufsky AM. Gomez Marti JL, et al. Among authors: nasrazadani a. EBioMedicine. 2021 Aug;70:103489. doi: 10.1016/j.ebiom.2021.103489. Epub 2021 Jul 16. EBioMedicine. 2021. PMID: 34280778 Free PMC article. No abstract available.
34 results